

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number  
**WO 2005/033082 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 215/00**

(21) International Application Number:  
PCT/IB2004/003054

(22) International Filing Date:  
20 September 2004 (20.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/507,385 30 September 2003 (30.09.2003) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DALVIE, Deepak, Kamalnath** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **RUGGERI, Roger, Benjamin** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; c/o Lawrence, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CETP INHIBITORS AND METABOLITES THEREOF

(57) Abstract: Compounds resulting from the administration of torcetrapib to a mammal, and the use of such compounds as an indicator or biomarker to the presence or exposure of torcetrapib in the plasma of a mammal including humans. The invention is also directed to cholesteryl ester transfer protein (CET P) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides.

WO 2005/033082 A2

5

**CETP INHIBITORS AND METABOLITES THEREOF****Background of the Invention**

The invention relates to one or more compounds resulting from the administration of 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, hereafter "torcetrapib", to a mammal. The compounds can therefore be used as an indicator or biomarker to the presence or exposure of torcetrapib in plasma of a mammal including humans.

This invention also relates to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides. Accordingly, the CETP inhibitors can be used to treat diseases which are affected by low levels of HDL-cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in certain mammals, i.e., those mammals that have CETP in their plasma, including humans. Atherosclerosis and its associated coronary artery disease (CAD) is the leading cause of mortality in the industrialized world. Despite attempts to modify secondary risk factors, e.g., smoking, obesity, lack of exercise, and treatment of dyslipidemia with dietary modification and drug therapy, coronary heart disease (CHD) remains the most common cause of death in the U.S. Cardiovascular disease accounts for 44% of all deaths, with 53% of these associated with atherosclerotic coronary heart disease.

Risk for development of this condition has been shown to be strongly correlated with certain plasma lipid levels. Elevated LDL-cholesterol is recognized as a significant contributor to CHD. Low HDL-cholesterol is also a known risk factor for CHD (Gordon, D. J., et al., "High-density Lipoprotein Cholesterol and Cardiovascular Disease", *Circulation*, (1989), 79: 8-15). High LDL-cholesterol and triglyceride levels are positively correlated, while high levels of HDL-cholesterol are negatively correlated with the risk for developing cardiovascular diseases. Thus,

5     dyslipidemia is not a unitary risk profile for CHD but may be comprised of one or more lipid aberrations.


          Among the many factors controlling plasma levels of these disease dependent principles, cholesteryl ester transfer protein (CETP) activity affects all three. The role of this 70,000 dalton plasma glycoprotein found in a number of  
10    animal species, including humans, is to transfer cholesteryl ester and triglyceride between lipoprotein particles, including high density lipoproteins, low density lipoproteins, very low density lipoproteins (VLDL), and chylomicrons. The net result of CETP activity is a lowering of HDL-cholesterol and an increase in LDL-cholesterol. This effect on lipoprotein profile is believed to be pro-atherogenic,  
15    especially in subjects whose lipid profile constitutes an increased risk for CHD.

          EP0818448 (970624) discloses the preparation of certain 5,6,7,8 substituted tetrahydroquinolines and their use as CETP inhibitors. U.S. Pat. No. 5,231,102 discloses a class of 4-substituted 1,2,3,4-tetrahydroquinolines that possess an acidic group (or group convertible thereto in vivo) at the 2-position that are specific  
20    antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment and/or prevention of neurodegenerative disorders. U.S. Pat. No. 5,288,725 discloses pyrroloquinoline bradykinin antagonists.

          Although there are a variety of anti-atherosclerosis therapies, there is a continuing need and a continuing search in this field of art for alternative therapies.  
25    U.S. Patent No. 6,197,786 discloses a class of substituted-3,4-dihydro 2H-quinolines as CETP inhibitors. Of particular interest is torcetrapib, and its use for raising levels of HDL-cholesterol or lowering levels of LDL-cholesterol. Accordingly, there exists a need to monitor the presence or exposure of torcetrapib in the plasma of humans.

### 30    **Summary of the Invention**

          This invention is directed to a compound of Formula I



wherein

$R^1$  is  $-\text{CO}_2\text{CH}_3$  or  $-\text{H}$ ;

$R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $-\text{CH}_2\text{CH}_2\text{OA}$ , wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and

$R^3$  is  $-\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$  and  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ ; or a pharmaceutically acceptable salt of said compound with the proviso that

if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{H}$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and  $-\text{CH}_2\text{CO}_2\text{H}$ ;

if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_2$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and  $-\text{CH}_2\text{CO}_2\text{H}$ ; and

if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^2$  is  $-\text{CH}_2\text{CH}_3$ , then  $R^3$  is not  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ , and  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ .

Preferred compounds of Formula I include compounds wherein

$R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CO}_2\text{A}$  or  $-\text{CH}_2\text{CH}_2\text{OA}$ ;

$R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^3$  is  $-\text{H}$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CO}_2\text{A}$  or  $-\text{CH}_2\text{CH}_2\text{OA}$ ;

$R^1$  and  $R^3$  is  $\text{H}$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $-\text{CH}_2\text{CH}_2\text{OA}$ ; and


$R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^2$  is  $-\text{CH}_2\text{CH}_3$ , and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ .

The invention is also directed to a compound selected from the following list of compounds. At times each respective compound in this list is referred to herein as a compound-A:

[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;

- 5 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;  
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;  
 10 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;  
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; and  
 [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid  
 15


The invention is also directed to a compound of Formula II



- wherein R<sup>5</sup> is -CH<sub>2</sub>CH<sub>3</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>A, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CO<sub>2</sub>H, -CH<sub>2</sub>CH<sub>2</sub>OA, -CH<sub>2</sub>CH<sub>2</sub>OSO<sub>3</sub>H, -C(O)N(H)CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H, -C(O)N(H)CH<sub>2</sub>CO<sub>2</sub>H, and -C(O)N(H)C(O)NH<sub>2</sub>, wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.  
 20

Preferred compounds of Formula II include the compounds wherein R<sup>5</sup> is selected from -CH<sub>2</sub>CH<sub>3</sub> or -CO<sub>2</sub>H.

The invention is also directed to a compound of Formula III



- wherein R<sup>6</sup> is -CH<sub>2</sub>OA, -C(O)N(H)CH<sub>2</sub>CO<sub>2</sub>A and -CH(SO<sub>3</sub>H)N(H)CO<sub>2</sub>CH<sub>3</sub>, wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.  
 25

- The invention is also directed to a method for indicating the presence or exposure of 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, i.e., torcetrapib, in plasma of a mammal including humans by the identification or  
 30

5 monitoring of one or more compounds selected from the compounds of Formula I, Formula II, Formula III, a compound-A, or 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in the mammal. As a result, these compounds can be used as an indicator  
10 or biomarker to the presence or exposure of torcetrapib in plasma of a mammal.

One method of the invention includes indicating the presence or exposure of torcetrapib in a mammal by identifying or monitoring a compound of Formula I in the mammal.

Another method of the invention includes indicating the presence or  
15 exposure of torcetrapib in a mammal by identifying or monitoring a compound-A or 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in the mammal.

Another method of the invention includes indicating the presence or  
20 exposure of torcetrapib in a mammal by identifying or monitoring a compound of Formula II, 2-methyl-6-trifluoromethyl-quinoline, or (6-trifluoromethyl-quinolin-2-yl)methanol in the mammal.

Another method of the invention includes indicating the presence or  
25 exposure of torcetrapib in a mammal by identifying or monitoring a compound selected from 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-benzyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, (3,5-Bis-trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid, (3,5-Bis-trifluoromethyl-benzoylamino)-acetic acid, or (3,5-Bis-trifluoromethyl-benzoylamino)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid in the mammal.  
30

Another method of the invention includes indicating the presence or  
exposure of torcetrapib in a mammal by identifying or monitoring a compound  
35 selected from

- 5 3,5-bis-trifluoromethylbenzoic acid, 2-methyl-6-trifluoromethyl-quinoline, and  
6-trifluoromethyl-quinoline-2-carboxylic acid in the mammal.

The invention is also directed to a method for treating atherosclerosis in a mammal comprising administering to a mammal an atherosclerosis treating amount of a compound selected from Formula I, a prodrug thereof, or a pharmaceutically acceptable amount salt of said compound or of said prodrug. The compounds of  
10 Formula I are inhibitors of CETP.

The invention is also directed to a method for treating atherosclerosis in a mammal comprising administering to a mammal an atherosclerosis treating amount of a compound-A, a prodrug thereof, or a pharmaceutically acceptable amount salt of said compound or of said prodrug. Any one compound-A can be used to inhibit  
15 CETP.

A preferred dosage is about 0.001 to 100 mg/kg/day of a compound of Formula I or of compound-A, a prodrug thereof, or a pharmaceutically acceptable salt of said compound of Formula I or of compound-A or of said prodrug. An  
20 especially preferred dosage is about 0.01 to 10 mg/kg/day of a compound of Formula I or of compound-A, a prodrug thereof, or a pharmaceutically acceptable salt of said compound of Formula I or of compound-A or of said prodrug.

The term "treating", "treat" or "treatment" as used herein includes preventative (e.g., prophylactic) and palliative treatment.

25 By "pharmaceutically acceptable" is meant the carrier, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.

The expression "prodrug" refers to compounds that are drug precursors which following administration, release the drug in vivo via some chemical or  
30 physiological process (e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the desired drug form). Exemplary prodrugs upon cleavage release the corresponding free acid, and such hydrolyzable ester-forming residues of the compounds of Formula I and of a compound-a.

The expression "pharmaceutically-acceptable salt" refers to nontoxic anionic  
35 salts containing anions such as (but not limited to) chloride, bromide, iodide, sulfate,

5 bisulfate, phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, methanesulfonate and 4-toluene-sulfonate. The expression also refers to nontoxic cationic salts such as (but not limited to) sodium, potassium, calcium, magnesium, ammonium or protonated benzathine (N,N'-dibenzylethylenediamine), choline, ethanolamine, diethanolamine, ethylenediamine, meglamine (N-methyl-  
10 glucamine), benethamine (N-benzylphenethylamine), piperazine or tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol).

The chemist of ordinary skill will recognize that certain compounds of this invention will contain one or more atoms which may be in a particular stereochemical or geometric configuration, giving rise to stereoisomers and  
15 configurational isomers. All such isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are also included.

#### Detailed Description of the Invention

The compounds of Formula I, Formula II and Formula III are metabolites of  
20 torcetrapib. As a result, these compounds (metabolites) can be used as biomarkers to the presence or exposure of torcetrapib in the plasma of mammals including humans by identifying or monitoring the presence of one or more compounds selected from compounds of Formula I, Formula II or Formula III in the mammal. The compounds of Formula I, Formula II and Formula III can be isolated from the  
25 plasma, feces or urine of mammals following administration, preferably oral administration, of torcetrapib to the mammals including humans. Consequently, the compounds of Formula I, Formula II and Formula III can be prepared by administering torcetrapib to a human or other mammal and isolating the desired compound (metabolite) from plasma, urine, or feces from the human subject or  
30 mammal. The compounds of Formula I, Formula II and Formula III can also be synthetically prepared using methods described in this Application as well as alternative synthetic methods known to those of ordinary skill in the art. As a result, the metabolites of torcetrapib isolated from the administration of torcetrapib to a mammal can be structurally verified by comparison with the HPLC and/or mass  
35 spectroscopic data of the corresponding synthetically prepared compounds.



5           The following list compounds of the invention, referred to herein as a compound-A, are also metabolites of torcetrapib:

[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;

10           [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;

[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

15           [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;

[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; and

20           [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid.

As a result, any one compound-A can be used as a biomarker to the presence or exposure of torcetrapib in the plasma of mammals including humans by identifying or monitoring the presence of the compound in the mammal. Any one  
25   compound-A can be isolated from the plasma, feces, or urine of mammals following administration, preferably oral administration, of torcetrapib to the mammals including humans. Consequently, any one compound-A can be prepared by administering torcetrapib to a human or other mammal and isolating the compound from plasma, urine, or feces from the human subject or mammal. Any one  
30   compound-A can also be synthetically prepared using methods described in this Application as well as alternative synthetic methods known to those of ordinary skill in the art. As a result, these specific metabolites of torcetrapib isolated from the administration of torcetrapib to a mammal can be structurally verified by comparison with the HPLC and/or mass spectroscopic data of the synthetically  
35   prepared compounds.

5           The compounds 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-benzyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid,  
          (3,5-Bis-trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid,  
10       (3,5-Bis-trifluoromethyl-benzoylamino)-acetic acid, 2-methyl-6-trifluoromethyl-quinoline, (6-trifluoromethyl-quinolin-2-yl)methanol, or (3,5-Bis-trifluoromethyl-benzoylamino)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid are also  
          metabolites of torcetrapib. These compounds can be isolated from the plasma, feces,  
          or urine of mammals following administration, preferably oral administration, of  
15       torcetrapib to the mammals including humans. Consequently, the compounds can be  
          prepared by administering torcetrapib to a human or other mammal and isolating the  
          compound from plasma, urine, or feces from the human subject or mammal.

          As a result, any one compound selected from 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-trihydroxy-tetrahydro-  
20       pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-benzyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, (3,5-Bis-trifluoromethyl-phenyl)-  
          methoxycarbonylamino-methanesulfonic acid, (3,5-Bis-trifluoromethyl-benzoylamino)-acetic acid, 2-methyl-6-trifluoromethyl-quinoline, (6-trifluoromethyl-quinolin-2-yl)methanol, or (3,5-Bis-trifluoromethyl-benzoylamino)-  
25       3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid can be used as a biomarker to  
          the presence or exposure of torcetrapib in the plasma of mammals including humans  
          by identifying or monitoring the presence of at least one of the listed compounds in  
          the mammal.

          As an initial note, some of the preparation methods used in the preparation of  
30       the compounds of the invention may require protection of remote functionality (e.g.,  
          primary amine, secondary amine, carboxyl, or hydroxyl). The need for such  
          protection will vary depending on the nature of the remote functionality and the  
          conditions of the preparation methods. The need for such protection is readily  
          determined by one skilled in the art. The use of such protection/deprotection  
35       methods is also within the skill in the art. For a general description of protecting

5 groups and their use, see T. W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, New York, 1991.

For example, in reaction Schemes 1 to 4 certain compounds contain primary amines or carboxylic acid functionalities which may interfere with reactions at other sites of the molecule if left unprotected. Accordingly, such functionalities may be  
10 protected by an appropriate protecting group which may be removed in a subsequent step. Suitable protecting groups for amine and carboxylic acid protection include those protecting groups commonly used in peptide synthesis (such as N-t-butoxycarbonyl, benzyloxycarbonyl, and 9-fluorenylmethyloxycarbonyl for amines and lower alkyl or benzyl esters for carboxylic acids) which are generally not  
15 chemically reactive under the reaction conditions described and can typically be removed without chemically altering other functionality in the compound.

In general the compounds of this invention can be made by processes which include processes analogous to those known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the  
20 compounds of this invention are provided as further features of the invention and are illustrated by reaction Schemes 1 to 4. Detailed synthetic procedures used to prepare one or more compounds of Formula I, Formula II, Formula III and of a compound-A are described in the Example section of this Application.

The compounds of Formula I and of compound-A can be prepared according  
25 to the synthetic procedures described in U.S. Patent No. 6,197,786, and U.S. patent application serial no. 10/137,314, the entire disclosures of which are incorporated herein by reference.

In particular, the tetrahydroquinoline ring system is prepared by treating the appropriate aromatic amine with the requisite carboxaldehyde in an inert solvent  
30 such as a hydrocarbon (e.g., hexanes, pentanes or cyclohexane), an aromatic hydrocarbon, a halocarbon, an ether, a nitrile, a nitroalkane, preferably dichloromethane with a dehydrating agent (e.g., sodium sulfate or magnesium sulfate) at a temperature of about 0 °C to about 100 °C (preferably ambient temperature) for 1 to 24 hours (preferably 1 hour). The resulting solution is treated  
35 with a suitably substituted (e.g., benzyloxycarbonyl, t-butoxycarbonyl,

5 methoxycarbonyl, formyl-, acetyl-, diallyl- or dibenzyl-), preferably  
carboxybenzyloxy-, N-vinyl species and with a Lewis acid (e.g., boron trifluoride,  
boron trifluoride etherate, zinc chloride, titanium tetrachloride, iron trichloride,  
aluminum trichloride, alkyl aluminum dichloride, dialkyl aluminum chloride or  
ytterbium (III) triflate; preferably boron trifluoride etherate) or a protic acid at a  
10 temperature of from about -78 °C to about 50 °C (preferably ambient temperature)  
for 0.1 to 24 hours (preferably 1 hour).

The resulting 6-trifluoromethyl quinoline ring system ring with the  
appropriate R<sup>2</sup> substituent is then reacted with 3,5-bis-trifluoromethyl benzaldehyde  
in a reductive condensation reaction as indicated in-part in Scheme 1.

15 Alternatively, the aromatic amine and appropriate carboxaldehyde may be  
condensed in the presence of 1H-benzotriazole by combining the three components  
in a suitable solvent (preferably toluene) as shown in-part in Scheme 1. The reaction  
is typically conducted at a temperature between 0 and reflux (preferably about  
ambient temperature) for between 15 minutes and 24 hours (preferably about 2  
20 hours). The reaction apparatus is optionally equipped for the azeotropic removal of  
water. After the reaction is at or near completion, as indicated by TLC, GC, NMR  
or other means, the reaction mixture is concentrated to afford the imine-  
benzotriazole adduct. The residue is slurried in a nonpolar solvent (preferably  
hexanes) and the resulting suspension collected by filtration. The resulting imine-  
25 benzotriazole adduct can then be used to prepare the desired tetrahydroquinoline  
system of Formula 1 or Compound-A.

The compounds of Formula I and of compound-A in which R<sup>2</sup> is not -  
CH<sub>2</sub>CH<sub>3</sub> can be prepared from Intermediate A, Intermediate B, or Intermediate C,  
whose multi-step synthesis is summarized in Scheme 1. A ring-closing step is used  
30 to form the  
6-trifluoromethyl quinoline ring system followed by a reductive condensation  
reaction with 3,5-bis-trifluoromethyl benzaldehyde. Standard chemical conversions,  
such as those described in U.S. Patent No. 6,197,786 and in the preparation of  
glucoronidated products, can be used to convert these intermediates to the desired  
35 compounds of Formula I and compound-A.


5           For example, compound **19** can be prepared from Intermediate C in three basic steps: (1) hydrogenation over Pd/C providing compound **24**; (2) protection of the alcohol; and (3) esterification of the quinoline-nitrogen. Compounds **21** and **26** can be prepared from compounds **19** and **24**, respectively, with known procedures to convert an alcohol into a carboxylic acid.

10           The glycoside compounds **20** and **25** can be prepared from compounds **19** and **24**, respectively, by the reaction of the alcohol and carbohydrate in an inert solvent such as toluene. An alternative procedure is the reaction of the alcohol with a protected glycosyl halide in the presence of base followed by deprotection. Similarly, glycoside compounds **22**, **27** and **32** can be prepared from compounds **21**,  
15   **26** and **31**, respectively, by the reaction of the acid and carbohydrate. Finally, the glycoside compounds can be prepared according to the in-vitro enzymatic procedure described in the Example section of this Application.


          The 2-substituted-6-trifluoromethyl-quinoline compounds of Formula II can be prepared in accordance with Schemes 2, 3 or 4. The compound numbers  
20   identified in Schemes 2, 3 and 4 correspond to the compound numbers provided in Tables 2 and 3. The 2-(6-trifluoromethyl)-quinolin-2-yl)-amide compounds **12**, **13** and **14** can be prepared from the corresponding acid, compound **11**, using synthetic procedures well known to those of ordinary skill in the art.

          The 1,3,5-trisubstituted phenyl compounds of Formula III can be prepared  
25   starting from 3,5-bis-trifluoromethyl benzaldehyde using synthetic procedures well known to those of ordinary skill in the art. 3,5-bis-trifluoromethylbenzoic acid can be prepared according to the procedure described in U.S. Patent No. 6,489,507, of which the entire disclosure is incorporated herein by reference.


## Scheme 1




## Scheme 2



## Scheme 3



## Scheme 4



5 prepared according to methods known to those skilled in the art. For example, a carboxyl group in a carboxylic acid of a compound of Formula I or a compound-A can be replaced by an ester prepared by combining the carboxylic acid with the appropriate alkyl halide in the presence of a base such as potassium carbonate in an inert solvent. Alternatively, an alcohol function can be derivatized as an ether  
10 prepared by combining the alcohol with the appropriate alkyl bromide or iodide in the presence of a base such as potassium carbonate in an inert solvent.

The starting materials and reagents for compounds of Formula I, Formula II, Formula III and of any one compound-A are readily available or can be easily synthesized by those skilled in the art using conventional methods of organic  
15 synthesis. For example, many of the compounds used herein, are related to, or are derived from compounds in which there is a large scientific interest and commercial need, and accordingly many such compounds are commercially available or are reported in the literature or are easily prepared from other commonly available substances by methods which are reported in the literature.

20 Some of the compounds of Formula I, Formula II, Formula III, and of a compound-A, or intermediates in their synthesis have asymmetric carbon atoms and therefore are enantiomers or diastereomers. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known per, example, by chromatography and/or fractional  
25 crystallization. Enantiomers can be separated by, for example, chiral HPLC methods or converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, a racemic mixture of the compounds of  
30 Formula I, Formula II, Formula III or of a compound-A, or an intermediate in their synthesis which contain an acidic or basic moiety may be separated into their compounding pure enantiomers by forming a diastereomeric salt with an optically pure chiral base or acid (e.g., 1-phenyl-ethyl amine or tartaric acid) and separating the diastereomers by fractional crystallization followed by neutralization to break  
35 the salt, thus providing the corresponding pure enantiomers. All such isomers,



5 including diastereomers, enantiomers and mixtures thereof are considered as part of this invention.

More specifically, the enantiomeric compounds of Formula I, Formula II, Formula III and of a compound-A can be obtained in enantiomerically enriched form by resolving the racemate of the final compound or an intermediate in its  
10 synthesis (preferably the final compound) employing chromatography (preferably high pressure liquid chromatography [HPLC]) on an asymmetric resin (preferably Chiralcel<sup>TM</sup> AD or OD [obtained from Chiral Technologies, Exton, Pa.]) with a mobile phase consisting of a hydrocarbon (preferably heptane or hexane) containing between 0 and 50% isopropanol and between 0 and 5% of an alkyl amine.

15 Concentration of the product containing fractions affords the desired materials.

Some of the compounds of Formula I, Formula II, Formula III and of a compound-A are acidic and they form a salt with a pharmaceutically acceptable cation. Likewise, some of the compounds of Formula I, Formula II, Formula III and of a compound-A are basic and they form a salt with a pharmaceutically acceptable  
20 anion. All such salts are within the scope of this invention and they can be prepared by conventional methods such as combining the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non- aqueous or partially aqueous medium, as appropriate. The salts are recovered either by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent, or, in the  
25 case of aqueous solutions, by lyophilization, as appropriate. The compounds can be obtained in crystalline form by dissolution in an appropriate solvent(s) such as ethanol, hexanes -an or water/ethanol mixtures. In addition, if a compound of Formula I, Formula II, Formula III or of a compound-A form hydrates or solvates, the hydrates and solvates are also within the scope of the invention.

30 The compounds of Formula 1 and any one of compound-A and the salts of such compounds can be adapted to therapeutic use as agents that inhibit CETP activity in mammals, particularly humans or can be used as an indicator of the active CETP inhibitor in their plasma. These compounds elevate plasma HDL cholesterol, its associated components, and the functions performed by them in mammals,  
35 particularly humans. By virtue of their activity, these agents also reduce plasma

5 levels of triglycerides, VLDL cholesterol LDL-cholesterol and their associated components in mammals, particularly humans. Hence, these compounds are useful for the treatment and correction of the various dyslipidemias observed to be associated with the development and incidence of atherosclerosis and cardiovascular disease, including hypoalphalipoproteinemia, hyperbetalipoproteinemia, 10 hypertriglyceridemia, and familial- hypercholesterolemia.

Given the negative correlation between the levels of HDL cholesterol and HDL associated lipoproteins, and the positive correlation between triglycerides, LDL- cholesterol, and their associated apolipoproteins in blood with the development of cardiovascular, cerebral vascular and peripheral vascular diseases, 15 compounds of Formula I compounds or of any one compound-A and the salts of such compounds, by virtue of their pharmacologic action, are useful for the prevention, arrestment and/or regression of atherosclerosis and its associated disease states. These include cardiovascular disorders (e.g., angina, cardiac ischemia and myocardial infarction), complications due to cardiovascular disease therapies (e.g., 20 reperfusion injury and angioplastic restenosis), hypertension, stroke, and atherosclerosis associated with organ transplantation.

Because of the beneficial effects widely associated with elevated HDL levels, an agent which inhibits CETP activity in humans, by virtue of its HDL increasing ability, also provides valuable avenues for therapy in a number of other 25 disease areas as well.

The utility of compounds of Formula I or of any one compound-A, their prodrugs and the salts of such compounds and prodrugs as medical agents in the treatment of the above described disease/conditions in mammals (e.g. humans, male or female) is demonstrated by the activity of the compounds of this invention in 30 conventional assays and the in vivo assay described below. The in vivo assay (with appropriate modifications within the skill in the art) may be used to determine the activity of other lipid or triglyceride controlling agents as well as the compounds of this invention. Such assays also provide a means whereby the activities of the compounds and the salts of such compounds (or the other agents described herein) 35 can be compared to each other and with the activities of other known compounds.

- 5 The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases.

The hyperalphacholesterolemic activity of compounds of Formula I or of any one compound-A can be determined by assessing the effect of these compounds on the action of cholesteryl ester transfer protein by measuring the relative transfer ratio  
10 of radiolabeled lipids between lipoprotein fractions, essentially as previously described by Morton in *J. Biol. Chem.* 1981 256, 11992, and by Dias in *Clin. Chem* 1988, 34,2322, 1988.

1. CETP In-vitro Assay.

The following is a brief description of the assay of cholesteryl ester transfer  
15 in human plasma (in vitro) and animal plasma (ex vivo): CETP activity in the presence or absence of drug is assayed by determining the transfer of 3H- labeled cholesteryl oleate (CO) from exogenous tracer HDL to the non-HDL lipoprotein fraction in human plasma, or from 3H-labeled LDL to the HDL fraction in transgenic mouse plasma. Labeled human lipoprotein substrates are prepared  
20 similarly to the method described by Morton in which the endogenous CETP activity in plasma is employed to transfer 3H-CO from phospholipid liposomes to all the lipoprotein fractions in plasma. 3H-labeled LDL and HDL are subsequently isolated by sequential ultracentrifugation at the density cuts of 1.019-1.063 and 1.10-1.21 g/ml, respectively. For the activity assay, 3H- labeled lipoprotein is added to  
25 plasma at 10-25 nmoles CO/ml and the samples incubated at 37° C for 2.5-3 hrs. Non-HDL lipoproteins are then precipitated by the addition of an equal volume of 20% (wt/vol) polyethylene glycol 8000 (Dias). The samples are centrifuged 750 g x 20 minutes and the radioactivity contained in the HDL containing supernatant determined by liquid scintillation. Introducing varying quantities of the compounds  
30 of this invention as a solution in dimethylsulfoxide to human plasma, before addition of the radiolabeled cholesteryl oleate, and comparing the relative amounts of radiolabel transferred allows relative cholesteryl ester transfer inhibitory activities to be determined.

2. Plasma Lipids Assay.

35 The activity of these compounds may also be demonstrated by determining

5 the amount of agent required to alter plasma lipid levels, for example HDL cholesterol levels, LDL cholesterol levels, VLDL cholesterol levels or triglycerides, in the plasma of certain mammals, for example marmosets that possess CETP activity and a plasma lipoprotein profile similar to that of humans (Crook et al. *Arteriosclerosis* 1990 10, 625.). Adult marmosets are assigned to treatment groups  
10 so that each group has a similar mean  $\pm$ SD for total, HDL, and/or LDL plasma cholesterol concentrations. After group assignment, marmosets are dosed daily with compound as a dietary admix or by intragastric intubation for from one to eight days. Control marmosets receive only the dosing vehicle. Plasma total, LDL, VLDL and HDL cholesterol values can be determined at any point during the study by  
15 obtaining blood from an antecubital vein and separating plasma lipoproteins into their individual subclasses by density gradient centrifugation, and by measuring cholesterol concentration as previously described by Crook et al.

### 3. In-vivo Atherosclerosis Assay.

Anti-atherosclerotic effects of the compounds can be determined by the  
20 amount of compound required to reduce the lipid deposition in rabbit aorta. Male New Zealand White rabbits are fed a diet containing 0.2% cholesterol and 10% coconut oil for 4 days (meal-fed once per day). Rabbits are bled from the marginal ear vein and total plasma cholesterol values are determined from these samples. The rabbits are then assigned to treatment groups so that each group has a similar mean  
25  $\pm$ SD for total plasma cholesterol concentration, HDL cholesterol concentration, triglyceride concentration and/or cholesteryl ester transfer protein activity. After group assignment, rabbits are dosed daily with compound given as a dietary admix or on a small piece of gelatin based confection. Control rabbits receive only the dosing vehicle, be it the food or the gelatin confection. The cholesterol/coconut oil  
30 diet is continued along with the compound administration throughout the study. Plasma cholesterol values and cholesteryl ester transfer protein activity can be determined at any point during the study by obtaining blood from the marginal ear vein. After 3-5 months, the rabbits are sacrificed and the aortae are removed from the thoracic arch to the branch of the iliac arteries. The aortae are cleaned of  
35 adventitia, opened longitudinally and then stained with Sudan IV as described by

5 Holman et. al. (*Lab. Invest.* 1958, 7, 42-47). The percent of the surface area stained is quantitated by densitometry using an Optimas Image Analyzing System (Image Processing Systems). Reduced lipid deposition is indicated by a reduction in the percent surface area stained in the compound-receiving group in comparison with the control rabbits.

10 Administration of the compounds of Formula I or of any one compound-A can be administered via any method which delivers a compound of this invention systemically and/or locally. These methods include oral routes, parenteral, intraduodenal routes, etc. Generally, the compounds of this invention are administered orally, but parenteral administration (e.g., intravenous, intramuscular, 15 subcutaneous or intramedullary) may be utilized, for example, where oral administration is inappropriate for the target or where the patient is unable to ingest the drug.

In general an amount of an active CETP inhibitor is used that is sufficient to achieve the therapeutic effect desired (e.g., HDL elevation). An effective dosage for 20 the CETP inhibitors of this invention, their prodrugs and the salts of such compounds and prodrugs is in the range of 0.01 to 10 mg/kg/day, preferably 0.1 to 5 mg/kg/day.

The CETP inhibitors of this invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds together 25 with a pharmaceutically acceptable vehicle, diluent or carrier. Thus, the CETP inhibitors can be administered individually or together in any conventional oral, parenteral, rectal or transdermal dosage form.

For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets 30 containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate 35 and talc are often very useful for tableting purposes. Solid compositions of a

5 similar type are also employed as fillers in soft and hard- filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. A preferred formulation is a solution or suspension in an oil, for example olive oil, Miglyol<sup>TM</sup> or Capmul<sup>TM</sup>, in a soft gelatin capsule. Antioxidants may be added to prevent long term degradation as  
10 appropriate. When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

15 For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous,  
20 intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration),  
25 otherwise similar to the above parenteral solutions, are prepared.

Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see *Remington's Pharmaceutical Sciences*, Mack Publishing  
30 Company, Easter, Pa., 15th Edition (1975).

Pharmaceutical compositions according to the invention may contain 0.1%-95% of the compound(s) of this invention, preferably 1%-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound(s) according to the invention in an amount effective to treat the  
35 disease/condition of the subject being treated, e.g., atherosclerosis.

5

**Example Section**

1. Sample analysis for determining the metabolic profile of torcetrapib and the identification and preparation of the metabolites using HPLC/MS.

10 All mammals including human subjects were dosed with [ $^{14}\text{C}$ ] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, that is,  $^{14}\text{C}$ -labeled torcetrapib. The urine, feces and plasma of the mammals and human subjects was collected for metabolite profiling.

15 Feces: Fecal homogenates were pooled such that 90% or greater radioactivity was accounted for. Each pooled fecal sample was diluted with 30 mL acetonitrile and vortexed. The sample was centrifuged and the supernatant evaporated to about 1 mL in a turbovap at 35 °C under nitrogen. The process was repeated several times until >90% of the radioactivity was extracted. After adding  
20 10 mL of ethyl acetate into the tube for liquid-liquid extraction, the ethyl acetate layer was removed and evaporated in a turbovap at 35 °C under nitrogen. The process was repeated several times until >90% of the radioactivity is extracted. The residue obtained was reconstituted in ~ 0.3 mL of acetonitrile:H<sub>2</sub>O (3:1). An aliquot (about 100  $\mu\text{l}$ ) of the reconstituted sample was then injected into the HPLC column  
25 to separate and structurally identify the metabolites.

The percentage of metabolites in fecal extract was determined by measuring the radioactivity in the individual peaks that are separated on HPLC using  $\beta$ -RAM detector (IN/US, Win-flow). The  $\beta$ -RAM was operated in the homogeneous liquid scintillation counting mode with the addition of 3 mL/min of Tru-Count scintillation  
30 cocktail (IN/US) to the effluent post-UV detection.

Plasma: Plasma samples were pooled according to the method reported by Hamilton and co-workers, for profiling of circulating metabolites (Hamilton R. A. et. al. 1981). The pooled plasma samples were treated with acetonitrile (5-fold excess). The mixture was centrifuged and the supernatant evaporated to about 2 mL  
35 in a turbovap at 35 °C under nitrogen. The concentrated samples were loaded onto Isolute C18 SPE columns (500 mg) and the columns subsequently washed with

5 acetonitrile. The washing was continued so that >90% of the radioactivity was recovered from SPE columns. Both aqueous and acetonitrile fractions were evaporated to dryness. The residue from the aqueous fraction was dissolved in acetonitrile and centrifuged. The supernatant was mixed with the acetonitrile fraction and evaporated to dryness. The final residue was reconstituted in ~300  $\mu$ l  
10 of 2:1 acetonitrile:water. An aliquot (about 100  $\mu$ l) of the reconstituted sample was then injected into the HPLC column to separate and structurally identify the metabolites.

Urine: Urine was pooled such that greater than 90% of the excreted radioactivity was accounted for. The pooling was proportional to the volumes of  
15 urine collected at each time point. Pooled urine samples were precipitated with five fold the volume of acetonitrile and then centrifuged (3000 rpm for 10 min). The supernatants were evaporated in a turbovap at 35 °C under nitrogen. The residue obtained was reconstituted in about 0.5 mL of 1:1 acetonitrile:H<sub>2</sub>O. An aliquot (about 100  $\mu$ l) of the reconstituted sample was then injected into the HPLC column  
20 to separate and structurally identify the metabolites.

High Performance Liquid Chromatography: The HPLC system consisted of a HP-1100 solvent delivery pump, a HP-1100 membrane degasser, a HP-1100 autoinjector and an IN/US radioactive monitor ( $\beta$ -RAM). Chromatography was performed on a Zorbax C18 column (5 micron, 4.5 x 150 mm) by injecting 100  $\mu$ l of  
25 the reconstituted sample. The mobile phase was initially composed of acetonitrile (solvent A) and 10 mM ammonium formate (pH 2.0) (solvent B). The flow rate was 1.0 mL/min and separation was achieved at ambient temperature. The 60 minute gradient is summarized in Table 1.

**Table 1.**

Time (min)	% Solvent A (Acetonitrile)	% Solvent B (10 mM, Ammonium formate)
0-10	20	80
10-35	24	76
35-37	50	50
37-53	95	5.0
53-55	20	80



5           The system was allowed to equilibrate for 5 min prior to the next injection. The post-column eluate was split such that 95% of the flow was monitored continuously with a  $\beta$ -RAM online detector fitted with a liquid scintillation cell (IN/US). The remaining 5% of the flow was diverted to a PE SCIEX API 2000 mass spectrometer or Finnigan LCQ Ion Trap mass spectrometer. The peaks in the  
10   radiochromatogram were quantified using Winflow software (INUS, Riviera Beach, FL.) or LC-ARC software (AIM Research Company, DE) by measuring the radioactivity in the individual peaks separated on HPLC using  $\beta$ -RAM or LC-ARC. The radioactivity response was also recorded in real time by the mass spectrometer data system. This allowed simultaneous real time monitoring of radioactivity and  
15   the detection of the total ion chromatogram.









          All mass spectrometers were, unless mentioned otherwise, operated in the positive ion mode. Data was collected in the Q1 scanning, neutral loss scanning, precursor ion scanning, product ion scanning, multiple reaction monitoring scanning and data-dependent ion scanning modes, with instrument settings and potentials  
20   (e.g., collision energy) adjusted to provide optimal data in each mode.









          The metabolites in urine and plasma were quantified by measuring the individually separated radioactive peaks using LC-ARC system (Liquid Chromatography-Accurate Radioisotope Counting, AIM Research Company). The LC-ARC was operated in the homogeneous liquid scintillation counting mode with  
25   the addition of 2.5 mL/min of Tru-Count scintillation cocktail (IN/US) to the effluent post-UV detection. The percentage of metabolite M1 (BTFMBA) excreted in the urine was determined by quantifying the concentrations of BTFMBA in urine samples at each sampling time.





          Table 2 lists the metabolites of torcetrapib separated and identified by HPLC  
30   and mass spectroscopy, respectively. Table 2 also lists the HPLC retention time recorded for each metabolite identified by compound number in the third column of Table 2 using the separation conditions described above.



5

Table 2

Compound Structure	Compound Name	No.	Retention Time min
	3,5-Bis-trifluoromethylbenzoic acid	1	27
	6-(3,5-Bis-trifluoromethylbenzyloxy)-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid	2	15
	6-(3,5-Bis-trifluoromethylbenzyloxy)-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid	3	15
	(3,5-Bis-trifluoromethylphenyl)-methoxycarbonylamino-methanesulfonic acid	4	15-16
	2-(6-Trifluoromethyl-quinolin-2-yl)-ethanol	5	18
	3,4,5-Trihydroxy-6-[2-(6-trifluoromethyl-quinolin-2-yl)-ethoxy]-tetrahydropyran-2-carboxylic acid	6	16
	Sulfuric acid mono-[2-(6-trifluoromethyl-quinolin-2-yl)-ethyl] ester	7	18-19
	2-Methyl-6-trifluoromethyl-quinoline	9	15-16

	(6-Trifluoromethyl-quinolin-2-yl)-methanol	10	18
	6-Trifluoromethyl-quinoline-2-carboxylic acid	11	34-35
	2-[(6-Trifluoromethyl-quinoline-2-carbonyl)-amino]-ethanesulfonic acid	12	10-11
	[(6-Trifluoromethyl-quinoline-2-carbonyl)-amino]-acetic acid	13	17.5
	(6-Trifluoromethyl-quinoline-2-carbonyl)-urea	14	40
	6-Trifluoromethyl-quinoline-2-carboxylic acid 6-carboxy-3,4,5-trihydroxy-tetrahydro-pyran-2-yl ester	15	11-17.6
	4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester	16	46-47
	4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester	17	46-47

	<p>(3,5-Bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester</p>	<p>23</p>	<p>49-50</p>
	<p>(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester</p>	<p>24</p>	<p>45-48</p>
	<p>6-(2-{4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-ethoxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid</p>	<p>25</p>	<p>27</p>
	<p>{4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid</p>	<p>26</p>	<p>45-46</p>


	(3,5-Bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-amine	28	44
	2-[4-(3,5-Bis-trifluoromethyl-benzylamino)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl]-ethanol	29	42-43





5

Table 3 provides a list of metabolites of torcetrapib that were not specifically identified by the HPLC/mass spectroscopic metabolic profile. These compounds are expected to have a very short metabolic half-life, and thus, the compounds in the plasma, urine or feces are very difficult to detect. Nevertheless, these compounds

10 can be identified as metabolites of torcetrapib because of their association with the metabolic pathways made evident by the compounds identified in Table 2 or are likely metabolic precursors or end-products to the products in Table 2.

Table 3

Compound Structure	Compound Name	No.
	(6-Trifluoromethyl-quinolin-2-yl)-acetic acid	8

	<p>4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 6-carboxy-3,4,5-trihydroxy-tetrahydropyran-2-yloxycarbonylmethyl ester</p>	18
	<p>4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester</p>	19
	<p>4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-[2-(6-carboxy-3,4,5-trihydroxy-tetrahydropyran-2-yloxy)-ethyl]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester</p>	20
	<p>4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester</p>	21

	<p>4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-(6-carboxy-3,4,5-trihydroxy-tetrahydro-yloxy-carbonylmethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester</p>	22
	<p>6-(2-{4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetoxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid</p>	27
	<p>6-{2-[4-(3,5-Bis-trifluoromethyl-benzylamino)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl]-ethoxy}-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid</p>	30
	<p>[4-(3,5-Bis-trifluoromethyl-benzylamino)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl]-acetic acid</p>	31

	6-{2-[4-(3,5-Bis-trifluoromethyl)-benzylamino)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl]-acetoxy}-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid	32
	(6-Trifluoromethyl-quinolin-2-yl)-ethyl	33
	(3,5-Bis-trifluoromethyl-benzoylamino)-acetic acid	34

5

## 2. Synthetic procedures for selected compounds listed in Tables 2 and 3.

As used herein, the expressions "reaction-inert solvent" and "inert solvent" refers to a solvent or a mixture thereof which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

10

The terms "concentrated" and "evaporated" refer to removal of solvent at water aspirator pressure on a rotary evaporator with a bath temperature of less than 45° C. Reactions conducted at 0-20° C' or 0-25° C' were conducted with initial cooling of the vessel in an insulated ice bath which was allowed to warm to room temperature over several hours.

15

In accordance with reaction Schemes 1 to 4, a select number of compounds recited in Table 2 and Table 3 were prepared according to the following synthetic procedures. Many of the the compounds of Table 2 and Table 3 whose synthesis are not described in detail below can be prepared by those skilled in the art starting from one of the compounds provided below and using synthetic procedures well known to those of ordinary skill in the art.

20



5           An alternative synthetic route to the general class of [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinolines and analogs thereof is described in U.S. patent application no. 10/137,314 and U.S. Patent No. 6,197,786, of which the entire disclosures are incorporated herein by reference.

10

**6-Trifluoromethyl-quinoline-2-carboxylic acid (Compound 11).**

4-Trifluoromethyl-aniline (2.0 g, 12.4 mmol), n-butyl glyoxaldehyde (1.8 g, 13.7 mmol) and anhydrous sodium sulfate (2.5 g) was combined in 150 mL of dichloromethane. After stirring for 1 hour and filtering through Celite, the  
15 concentrated imine was dissolved in toluene and combined with 1-bromo-2-ethoxy-ethene (3.4 g, 22.4 mmol) and p-toluenesulfonic acid monohydrate (236 mg, 1.24 mmol). After stirring at reflux for 6 hours, the reaction mixture was diluted with ethyl acetate, washed with a saturated NaHCO<sub>3</sub> solution, dried over magnesium sulfate, filtered and concentrated to give a residue which was purified by  
20 chromatography on silica gel eluting with 0-10% ethyl acetate in hexanes to afford 1.5 g of 3-bromo-4-ethoxy-6-trifluoromethyl-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid butyl ester.

3-Bromo-4-ethoxy-6-trifluoromethyl-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid butyl ester (1.5 g, 3.54 mmol) was dissolved in 50 mL of THF and  
25 treated with DBU (1.0 mL). After 40 min, the reaction mixture was concentrated, taken up in ethyl acetate, and washed twice with 2N HCl. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography on silica, eluting with 5% ethyl acetate in hexanes to give 800 mg of 6-trifluoromethyl-quinoline-2-carboxylic acid butyl ester.

30           6-Trifluoromethyl-quinoline-2-carboxylic acid butyl ester (300 mg, 1.0 mmol) was dissolved in 10 mL of methanol and treated with 1.0 mL of a 2N NaOH solution. After stirring overnight, the volatiles were evaporated and the aqueous phase extracted with ethyl acetate. The aqueous phase was acidified with 1N HCl and extracted twice with ethyl acetate. The combined organic layers were dried over

5 magnesium sulfate, filtered and concentrated to give the title compound as a colorless solid.

LCMS (ESI+): 242 (MH+). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.08 (1H, dd, J = 8.7, 1.8 Hz), 8.31 (1H, d, J = 8.3 Hz), 8.36 (1H, d, J = 8.7 Hz), 8.48 (1H, s), 8.67 (1H, d, J = 8.3 Hz).

10

**(6-Trifluoromethyl-quinolin-2-yl)-methanol (Compound 10).**

6-Trifluoromethyl-quinoline-2-carboxylic acid butyl ester (100 mg, 0.35 mmol) was dissolved in 5 mL of methanol and sodium borohydride (57 mg, 1.57 mmol) was added. After 4 hours, the volatiles were evaporated and the residue  
15 dissolved in water and extracted with ethyl acetate. The combined organic phases were dried over magnesium sulfate, filtered and concentrated to provide the title compound.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.97 (2H, s), 7.42 (1H, d, J = 8.7 Hz), 7.91 (1H, dd, J = 8.8, 2.1 Hz), 8.16 (1H, s), 8.21 (1H, d, J = 9.1 Hz), 8.25 (1H, d, J = 8.7 Hz)

20

**2-Methyl-6-trifluoromethyl-quinoline (Compound 9).**

(6-Trifluoromethyl-quinolin-2-yl)-methanol (80 mg, 0.35 mmol) was dissolved in dichloromethane, cooled in an ice/water bath and treated with triethylamine (89 mg, 0.88 mmol) and acetyl chloride (55 mg, 0.71 mmol). After 1  
25 hr, the cooling bath was removed and the mixture stirred at room temperature. After 4 hours, the reaction mixture was diluted with more dichloromethane, washed with 1N HCl, twice with saturated sodium bicarbonate solution, and brine. The organic phase was dried over magnesium sulfate, filtered, and concentrated to give acetic acid 6-trifluoromethyl-quinolin-2-ylmethyl ester.

30 Acetic acid 6-trifluoromethyl-quinolin-2-ylmethyl ester (50 mg) was dissolved in

5 mL of ethanol and 5 mL of cyclohexene, and treated with 10% palladium on carbon

(10 mg, 50% water weight). After heating at reflux for 4 hours, the cooled mixture  
35 was filtered through Celite, concentrated and the residue purified by

5 chromatography on silica eluting with 5% ethyl acetate in hexanes to afford the title compound.

LCMS (EI): 211 (M). <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 2.83 (3H, s), 7.69 (1H, d, J = 8.3 Hz), 8.03 (1H, dd, J = 8.8, 1.9 Hz), 8.16 (1H, d, J = 9.1 Hz), 8.41 (1H, s), 8.57 (1H, d, J = 8.7 Hz).

10

**(3,5-Bis-trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid (Compound 4).**

3,5-Bis-trifluoromethyl-benzaldehyde (1.47 g, 6.1 mmol) and bis(ammonium)sulfinate were combined in 10 mL of water and heated at 50 °C.

15 After 2 hours, the reaction mixture was cooled in an ice/water bath and concentrated HCl was added to form a precipitate. After stirring for 10 min, the solid was collected by filtration, washed with 0.1N HCl, ether, and air dried to yield 1.51 g of amino-(3,5-bis-trifluoromethyl-phenyl)-methanesulfonic acid.

Amino-(3,5-bis-trifluoromethyl-phenyl)-methanesulfonic acid (110 mg, 0.34 mmol) was dissolved in 2 mL of water containing 100 mg of potassium carbonate and treated with methyl chloroformate (30 µL, 0.34 mmol). After stirring for 1 hour, the precipitate formed was collected by filtration and air dried to afford 93 mg of the title compound, presumably as its potassium salt.

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.69 (3H, s), 5.82 (1H, s), 7.89 (1H, s), 8.18 (2H, s)

25

**3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-(carbamic acid methyl ester (Compound 24).**

In accordance with Scheme 1, a mixture of 4-trifluoromethyl-aniline (5 g, 31 mmol) and 1H-benzotriazole (3.7 g, 31 mmol) in 50 mL of toluene was added to a solution of 3-benzyloxy-propionaldehyde (5.1 g, 31 mmol) in 50 mL of toluene. After stirring at room temperature for 2 hours, the mixture was concentrated and the residue triturated with hexanes to obtain (1-Benzotriazol-1-yl-3-benzyloxy-propyl)-(4-trifluoromethyl-phenyl)-amine.

(1-Benzotriazol-1-yl-3-benzyloxy-propyl)-(4-trifluoromethyl-phenyl)-amine (5.0 g, 11.76 mmol) and vinyl-carbamic acid benzyl ester (2.1 g, 11.76 mmol) were dissolved in 50 mL of dichloromethane and cooled to -15 °C. Borontrifluoride

35

5 etherate (167 mg, 1.18 mmol) was then added. After 2 hours at this temperature and 1 hour at room temperature, the reaction mixture was diluted with dichloromethane, washed with a saturated sodium bicarbonate solution, then brine, and dried over magnesium sulfate. The solution was then filtered and concentrated. The residue was purified by chromatography on silica eluting with 5-10% ethyl acetate in  
10 hexanes to give [2-(2-Benzyloxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid benzyl ester.

[2-(2-Benzyloxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid benzyl ester (2.0 g, 4.24 mmol) and pyridine (0.86 mL, 10.6 mmol) were combined in 40 mL of dichloromethane and cooled in an ice/water bath as  
15 trifluoroacetic anhydride (0.72 mL, 5.1 mmol) was added. After 2 hours the cooling bath was removed and after 1 hour further, the reaction mixture was washed with two portions of 1N HCl, saturated sodium bicarbonate solution, then brine, and dried over magnesium sulfate. The solution was filtered and concentrated to provide [2-(2-Benzyloxy-ethyl)-1-(2,2,2-trifluoro-acetyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid benzyl ester.  
20

[2-(2-Benzyloxy-ethyl)-1-(2,2,2-trifluoro-acetyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid benzyl ester (2.0 g, 3.45 mmol) in 60 mL of ethanol was combined with 10% palladium on carbon (300 mg, 50% wet wt.) and shaken under 50 psi of hydrogen gas in a Parr bottle. After 1 hour, the reaction  
25 mixture was filtered through Celite, concentrated and purified by chromatography on silica eluting with 50% ethyl acetate in hexanes to give 1-[4-Amino-2-(2-benzyloxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl]-2,2,2-trifluoro-ethanone.

1-[4-Amino-2-(2-benzyloxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl]-2,2,2-trifluoro-ethanone (1.0 g, 2.45 mmol) was combined with 3,5-bis-trifluoromethyl-benzaldehyde (0.4 mL, 2.45 mmol) in 70 mL of 1,2-dichloroethane. After 1.5 hours, the reaction mixture was treated with sodium triacetoxyborohydride  
30 (2.6 g, 12.25 mmol) and stirred overnight before adding an aqueous 2N KOH solution. The organic layer is separated, dried over magnesium sulfate, filtered and  
35

5 concentrated. The resulting residue was purified by chromatography on silica eluting with a 10% ethyl acetate in hexanes solution to provide 1-[2-(2-Benzyloxy-ethyl)-4-(3,5-bis-trifluoromethyl-benzylamino)-6-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl]-2,2,2-trifluoro-ethanone.

10

1-[2-(2-Benzyloxy-ethyl)-4-(3,5-bis-trifluoromethyl-benzylamino)-6-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl]-2,2,2-trifluoro-ethanone (1 g, 1.49 mmol) was dissolved in 25 mL of dichloromethane and cooled in an ice/water bath as pyridine (1 mL, 12.4 mmol) and methyl chloroformate (1 mL, 12.9 mmol) were  
15 added. After stirring overnight at room temperature, the reaction mixture was extracted with 2N HCl (twice), a saturated sodium bicarbonate solution, and brine then dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography on silica eluting with a 5% then a 10% ethyl acetate in hexanes solution to provide [2-(2-Benzyloxy-ethyl)-1-(2,2,2-trifluoro-acetyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-(3,5-bis-trifluoromethyl-benzyl)-carbamic acid methyl ester.

[2-(2-Benzyloxy-ethyl)-1-(2,2,2-trifluoro-acetyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-(3,5-bis-trifluoromethyl-benzyl)-carbamic acid methyl ester (1 g, 1.37 mmol) was dissolved in 25 mL of a solution consisting of methanol,  
25 tetrahydrofuran and water in a 3:1:1 ratio and treated with a 1N LiOH solution (10 mL, 10 mmol). After stirring for a day, the volatiles were evaporated and the aqueous phase extracted with ethyl acetate. The combined organic phases were dried over magnesium sulfate, filtered and concentrated. The resulting residue was purified by chromatography on silica eluting with a 10% ethyl acetate in hexanes  
30 solution to provide [2-(2-Benzyloxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-(3,5-bis-trifluoromethyl-benzyl)-carbamic acid methyl ester.

[2-(2-Benzyloxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-(3,5-bis-trifluoromethyl-benzyl)-carbamic acid methyl ester (700 mg, 1.10 mmol) was dissolved in 50 mL of anhydrous ethanol and shaken in a Parr bottle under 50  
35 psi of hydrogen gas. After 4 h, the reaction mixture was filtered through Celite,

- 5 concentrated and the resulting residue purified by chromatography on silica eluting with a 10% ethyl acetate in hexanes solution to provide the title compound.

LCMS (ESI+): 545 (MH+).

- 10 **4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester (Compound 19).**

- (3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester (500 mg, 0.92 mmol)  
15 was dissolved in 10 mL of anhydrous dimethylformamide and combined with imidazole (125 mg, 1.8 mmol) and tert-butyldimethylsilyl chloride (280 mg, 1.8 mmol). After stirring overnight, the reaction mixture was combined with water and extracted with ethyl acetate. The combined organics were dried over magnesium sulfate, filtered and concentrated to provide (3,5-Bis-trifluoromethyl-benzyl)-{2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-6-trifluoromethyl-1,2,3,4-tetrahydro-  
20 quinolin-4-yl]-carbamic acid methyl ester.

- (3,5-Bis-trifluoromethyl-benzyl)-{2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester (500 mg, 0.76 mmol) was dissolved in 250 ml of dichloromethane, and cooled  
25 in an ice/water bath as pyridine (0.5 mL) and ethyl chloroformate (1.0 mL) are added. After stirring for 1 h, the ice bath was removed and the reaction mixture allowed to warm to room temperature. After stirring overnight, the reaction mixture was washed with 2 N HCl, a saturated sodium bicarbonate solution, and brine before the organic phase was dried over magnesium sulfate, filtered and concentrated. The  
30 residue was purified by chromatography on silica eluting with a 5% then a 10% ethyl acetate in hexanes solution to provide 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester.

- 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-  
35 carboxylic acid ethyl ester (200 mg) was dissolved in 10 mL of tetrahydrofuran and

- 5 treated with tetrabutylammonium fluoride (1 mL of a 1 molar solution in tetrahydrofuran). After 1 h, the reaction mixture was concentrated, the residue partitioned between water and ethyl acetate, and the aqueous layer extracted further with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography on silica  
10 eluting with a 10% ethyl acetate in hexanes solution to provide the title compound.

**{4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid (Compound 21).**

- (3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-6-trifluoromethyl-  
15 1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester can be oxidized by one of a number of methods known to those skilled in the art (such as treatment of the alcohol as a solution in acetone with a chromic acid solution) to the desired carboxylic acid product.

- 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-  
20 6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester (Compound 26).

- 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester can  
25 be oxidized by one of a number of methods known to those skilled in the art (such as treatment of the alcohol as a solution in acetone with a chromic acid solution) to the desired carboxylic acid product.

- Preparation of the glycoside compounds of the invention by in vitro glucuronidation.**  
30


- A typical incubation mixture, in a final volume of 0.3 ml, contained 0.3 mg (dog) or 0.45 mg (human or rat) of liver microsomal protein, preincubated for 15 min with 0.045 mg of Brij 58, 20 mM MgCl<sub>2</sub>, 5 mM UDPGA, and 0.05 M Tris  
35 buffer, pH 7.0. The preincubation step with Brij 58 was found to be optimal for high enzyme activity. Unless otherwise specified, the reaction was started by the addition of the appropriate substrate following a three minute preincubation at 37 °C. Control experiments were performed by excluding either the microsomes or UDPGA

- 5 from the incubation mixtures. The reaction was terminated at appropriate time intervals by the addition of 0.8 ml of acetonitrile (ACN). The ACN extracts were evaporated to dryness and reconstituted, just before analysis, in the mobile phase (20% ACN in 25 mM ammonium acetate buffer, pH 4.5) for analysis by the HPLC method described above.
- 10 Incubations with human recombinant UGTs were performed using the same conditions as described above for human liver microsomes, except that the mixture contained 0.3 mg of UGTs and was incubated for up to sixty minutes at 37°C. Control incubations using microsomes isolated from the same cell line containing the vector, but without a cDNA insert, also were included.
- 15 For the purpose of isolation and purification of the glucuronides, large-scale incubations of the compounds (100  $\mu$ M; 20  $\times$  0.5-ml incubation) can be carried out with dog liver microsomes (2 mg/ml) and UDPGA (5mM) for 60 min. The ACN extracts are evaporated to dryness and reconstituted for analysis by LC-MS and LC-NMR spectroscopy.



## 5 We Claim:

1. A compound having the Formula I



wherein


- 10  $R^1$  is  $-\text{CO}_2\text{CH}_3$  or  $-\text{H}$ ;  
 $R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $-\text{CH}_2\text{CH}_2\text{OA}$ , wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and  
 $R^3$  is  $-\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$  and  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ ; or a pharmaceutically acceptable salt of said  
15 compound with the proviso that  
if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{H}$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}_2\text{CO}_2\text{H}$ ;  
if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_2$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}_2\text{CO}_2\text{H}$ ; and  
20 if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^2$  is  $-\text{CH}_2\text{CH}_3$ , then  $R^3$  is not  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ .

2. The compound of claim 1 wherein  $R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CO}_2\text{A}$  or  $-\text{CH}_2\text{CH}_2\text{OA}$ .  
25  
3. The compound of claim 1 wherein  $R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^3$  is  $-\text{H}$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CO}_2\text{A}$  or  $-\text{CH}_2\text{CH}_2\text{OA}$ .

4. The compound of claim 1 wherein  $R^1$  and  $R^3$  is  $\text{H}$ , and  $R^2$  is selected  
30 from the group consisting of  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $\text{CH}_2\text{CH}_2\text{OA}$ .

- 5           5.     The compound of claim 1 wherein  $R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  
and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ .
6.     A compound selected from the group consisting of
- 10       [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-  
trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;  
      [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-  
trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;  
      [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-  
carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl  
15     ester;  
      [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-  
tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;  
      [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-  
trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; and  
20     [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-  
trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid.


7.     A compound of Formula II



- 25       wherein  $R^5$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{A}$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  
 $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CH}_2\text{OA}$ ,  $-\text{CH}_2\text{CH}_2\text{OSO}_3\text{H}$ ,  $-\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CH}_2\text{SO}_3\text{H}$ ,  
 $\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CO}_2\text{H}$ , and  $-\text{C}(\text{O})\text{N}(\text{H})\text{C}(\text{O})\text{NH}_2$ , and wherein A is 3,4,5-trihydroxy-  
tetrahydropyran-2-carboxylic acid.

- 30       8.     The compound of claim 7 wherein  $R^5$  is selected from  $-\text{CH}_2\text{CH}_3$  or  
 $-\text{CO}_2\text{H}$ .

- 5           9.     A compound of Formula III



wherein  $R^6$  is  $-\text{CH}_2\text{OA}$ ,  $-\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CO}_2\text{A}$  and  $-\text{CH}(\text{SO}_3\text{H})\text{N}(\text{H})\text{CO}_2\text{CH}_3$ , and wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.

10

10.     A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 1 in the mammal.

15

11.     A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 6 or 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in the mammal.

20

12.     A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound selected from the group consisting of a compound of claim 7, 2-methyl-6-trifluoromethyl-quinoline, and (6-trifluoromethyl-quinolin-2-yl)methanol in the mammal.

25

30


13.     A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-

5 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising  
 monitoring the presence of a compound selected from the group consisting of  
 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-  
 trihydroxy-tetrahydro-pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-  
 benzyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, (3,5-Bis-  
 10 trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid, (3,5-Bis-  
 trifluoromethyl-benzoylamino)-acetic acid, and (3,5-Bis-trifluoromethyl-  
 benzoylamino)- 3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid in the mammal.

14. A method for indicating the presence of or exposure to 4-[(3,5-bis-  
 15 trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-  
 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising  
 monitoring the presence of a compound selected from the group consisting of  
 3,5-bis-trifluoromethylbenzoic acid, 2-methyl-6-trifluoromethyl-quinoline, and  
 6-trifluoromethyl-quinoline-2-carboxylic acid in the mammal.

20

15. A method for treating atherosclerosis comprising administering to a  
 mammal an atherosclerosis treating amount of a compound of Formula I



wherein

25  $R^1$  is  $-\text{CO}_2\text{CH}_3$  or  $-\text{H}$ ;  
 $R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $-\text{CH}_2\text{CH}_2\text{OA}$ , wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and  
 $R^3$  is  $-\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ ,  
 $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$  and  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ ; a prodrug thereof, or a pharmaceutically  
 30 acceptable salt of said compound or of said prodrug with the proviso that

- 5           if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{H}$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}_2\text{CO}_2\text{H}$ ;
- if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_2$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}_2\text{CO}_2\text{H}$ ; and
- if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^2$  is  $-\text{CH}_2\text{CH}_3$ , then  $R^3$  is not  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ , or
- 10    $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ , or a compound a compound selected from the group consisting of
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;
- 15   [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- 20   [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester;
- [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid, and
- a prodrug thereof, or a pharmaceutically acceptable amount salt of said compound or
- 25   of said prodrug.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number  
**WO 2005/033082 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 215/42**  
(21) International Application Number:  
PCT/IB2004/003054

(22) International Filing Date:  
20 September 2004 (20.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/507,385 30 September 2003 (30.09.2003) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DALVIE, Deepak, Kamalnath** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **RUGGERI, Roger, Benjamin** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; c/o Lawrence, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
16 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CETP INHIBITORS AND METABOLITES THEREOF

(57) Abstract: Compounds resulting from the administration of torcetrapib to a mammal, and the use of such compounds as an indicator or biomarker to the presence or exposure of torcetrapib in the plasma of a mammal including humans. The invention is also directed to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides.



WO 2005/033082 A3

# INTERNATIONAL SEARCH REPORT

Intern Application No  
PCT/IB2004/003054

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D215/42

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/17165 A1 (PFIZER PRODUCTS INC., USA) 30 March 2000 (2000-03-30) page 84; example 3E -----	1
X	WO 00/17164 A1 (PFIZER PRODUCTS INC., USA) 30 March 2000 (2000-03-30) page 83; example 7E page 94; example 80 -----	1
X	WO 02/11710 A2 (PFIZER PRODUCTS INC., USA) 14 February 2002 (2002-02-14) page 44, lines 4-7 -----	6
X	WO 03/000295 A2 (PFIZER PRODUCTS INC., USA) 3 January 2003 (2003-01-03) page 32, lines 32-34 -----	6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

7 December 2004

Date of mailing of the international search report

15. 04 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Zellner, A

# INTERNATIONAL SEARCH REPORT

Inte Application No  
PCT/IB2004/003054

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 2004/004777 A1 (PFIZER PRODUCTS INC., USA) 15 January 2004 (2004-01-15) page 8, lines 23-25 -----</p>	6



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB2004/003054

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 10–14 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Claim 15 is directed to a method of treatment of the human/animal body.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1–14

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-14

Compounds of formulae (I), (II) and (III) (claims 1-9) and  
methods according to claims 10-14  
---

2. claim: 15

A method for treating atherosclerosis  
---

## INTERNATIONAL SEARCH REPORT

Inter.

Application No

PCT/IB2004/003054

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0017165	A1	30-03-2000	AT 268324 T 15-06-2004
			AU 747715 B2 23-05-2002
			AU 5440399 A 10-04-2000
			BG 105429 A 31-12-2001
			BR 9913855 A 24-07-2001
			CA 2344248 A1 30-03-2000
			CN 1318057 A 17-10-2001
			CN 1515259 A 28-07-2004
			CZ 20010954 A3 12-12-2001
			DE 69917790 D1 08-07-2004
			DK 1114032 T3 16-08-2004
			EE 200100167 A 17-06-2002
			EP 1114032 A1 11-07-2001
			ES 2221420 T3 16-12-2004
			HR 20010200 A1 30-04-2002
			HU 0103512 A2 28-02-2002
			ID 27838 A 26-04-2001
			JP 3561474 B2 02-09-2004
			JP 2002526476 T 20-08-2002
			NO 20011349 A 14-05-2001
			NZ 509837 A 26-11-2002
			PL 346830 A1 25-02-2002
			PT 1114032 T 30-09-2004
			SI 1114032 T1 31-12-2004
			SK 3532001 A3 03-12-2001
			TR 200100780 T2 23-07-2001
			TW 502022 B 11-09-2002
			US 6140343 A 31-10-2000
			US 6489478 B1 03-12-2002
			ZA 200101745 A 02-05-2002
WO 0017164	A1	30-03-2000	AU 752566 B2 19-09-2002
			AU 5440199 A 10-04-2000
			BG 105428 A 31-01-2002
			BR 9913810 A 19-06-2001
			CA 2344350 A1 30-03-2000
			CN 1318058 A 17-10-2001
			CZ 20010955 A3 12-12-2001
			EA 4674 B1 24-06-2004
			EE 200100166 A 17-06-2002
			EP 1114031 A1 11-07-2001
			HR 20010201 A1 30-04-2002
			HU 0103506 A2 28-01-2002
			ID 28026 A 03-05-2001
			JP 2002526475 T 20-08-2002
			JP 2004339239 A 02-12-2004
			NO 20011350 A 09-05-2001
			NZ 509840 A 26-11-2002
			PL 347099 A1 25-03-2002
			SK 3542001 A3 04-06-2002
			TR 200100768 T2 23-07-2001
			US 6197786 B1 06-03-2001
			US 2004092550 A1 13-05-2004
			US 6586448 B1 01-07-2003
WO 0211710	A2	14-02-2002	AU 2914202 A 18-02-2002
			BG 107456 A 30-09-2003
			BR 0112828 A 01-07-2003

# INTERNATIONAL SEARCH REPORT

Inte Application No  
PCT/IB2004/003054

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 0211710	A2	CA 2417755 A1	14-02-2002	
		CN 1458840 A	26-11-2003	
		CZ 20030224 A3	18-02-2004	
		EE 200300052 A	15-12-2004	
		EP 1305007 A2	02-05-2003	
		HU 0300676 A2	28-08-2003	
		JP 2004505911 T	26-02-2004	
		NO 20030506 A	31-01-2003	
		NZ 523680 A	24-09-2004	
		SK 1032003 A3	04-05-2004	
		US 2003186952 A1	02-10-2003	
		US 2002103225 A1	01-08-2002	
		ZA 200300869 A	16-04-2004	
WO 03000295	A2	03-01-2003	BR 0210505 A	18-05-2004
			CA 2455288 A1	03-01-2003
			CZ 20033341 A3	13-10-2004
			EE 200400024 A	15-06-2004
			EP 1453544 A2	08-09-2004
			JP 2005500314 T	06-01-2005
			MX PA04000014 A	21-05-2004
			SK 15172003 A3	03-11-2004
			US 2003022944 A1	30-01-2003
WO 2004004777	A1	15-01-2004	AU 2003238622 A1	23-01-2004
			CA 2490988 A1	15-01-2004
			US 2004039018 A1	26-02-2004